American Journal of Respiratory and Critical Care Medicine

Racial Segregation and Respiratory Outcomes among Urban Black Residents with and at Risk of COPD. 2021

Update in Chronic Obstructive Pulmonary Disease in 2020. 2021

A Phase 3 Open-Label Study of ELX/TEZ/IVA in Children 6 Through 11 Years of Age With CF and at Least One F508del Allele. 2021

Urban–Rural Disparities in Deaths from Chronic Lower Respiratory Disease in the United States.  203:769-772. 2021

Association between inhaled corticosteroids and expiratory central airway collapse in smokers.  203:518-521. 2021

Reply to Mezidi et al..  203:392-394. 2021

Computed tomography–based airway surface area–to-volume ratio for phenotyping airway remodeling in chronic obstructive pulmonary disease.  203:185-191. 2021

Case Fatality Rates for Patients with COVID-19 Requiring Invasive Mechanical Ventilation.  203:54-66. 2021

Overlap of genetic risk between interstitial lung abnormalities and idiopathic pulmonary fibrosis.  200:1402-1413. 2021

Ivacaftor reverses airway mucus abnormalities in a rat model harboring a humanized G551D-CFTR.  202:1271-1282. 2020

The effect of inhaled corticosteroid withdrawal and baseline inhaled treatment on exacerbations in the IMPACT study a randomized, double-blind, multicenter clinical trial.  202:1237-1243. 2020

Reply to Suissa.  202:773-774. 2020

A fatal case of pneumocephalus during computed tomography-guided lung biopsy.  201:E83-E84. 2020

Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease.  201:1508-1516. 2020

Cystic fibrosis: Emergence of highly effective targeted therapeutics and potential clinical implications.  201:1193-1208. 2020

Reply to de Steenhuijsen Piters and Bogaert.  201:1311-1312. 2020

Predicting Pneumonia in Chronic Obstructive Pulmonary Disease Have We Unraveled the Network of Risks?.  201:1026-1027. 2020

Human Fetal Lungs Harbor a Microbiome Signature.  201:1002-1006. 2020

Disease progression modeling in chronic obstructive pulmonary disease.  201:294-302. 2020

Clinical development and research applications of the chronic obstructive pulmonary disease assessment test.  201:1058-1067. 2020

Females with cystic fibrosis demonstrate a differential response profile to ivacaftor compared with males.  201:996-998. 2020

Hyperoxia injury in the developing lung is mediated by mesenchymal expression of Wnt5A.  201:1249-1262. 2020

Reply to Gagnon et al..  201:120. 2020

Reply to moy.  200:1443-1444. 2019

Sugarcoating lung injury: A novel role for high-molecular-weight hyaluronan in pneumonia.  200:1197-1198. 2019

A genetic risk score associated with chronic obstructive pulmonary disease susceptibility and lung structure on computed tomography.  200:721-731. 2019

Arterial vascular pruning, right ventricular size, and clinical outcomes in chronic obstructive pulmonary disease a longitudinal observational study.  200:454-461. 2019

Chronic obstructive pulmonary disease in America's black population.  200:423-430. 2019

Video telehealth pulmonary rehabilitation intervention in chronic obstructive pulmonary disease reduces 30-day readmissions.  200:511-513. 2019

Update in pulmonary fibrosis 2018.  200:292-300. 2019

Exposure to greater air pollution when traveling abroad is associated with decreased lung function.  199:1570-1572. 2019

Update in chronic obstructive pulmonary disease 2018.  199:1462-1470. 2019

Imaging advances in chronic obstructive pulmonary disease insights from the genetic epidemiology of chronic obstructive pulmonary disease (COPDGene) study.  199:286-301. 2019

Life-course smoking trajectories and risk for emphysema in middle age: The CARDIA Lung study.  199:237-240. 2019

Reply to Eapen et al.: Dysfunctional immunity and microbial adhesion molecules in smoking-induced pneumonia.  199:251-252. 2019

Design of idiopathic pulmonary fibrosis clinical trials in the era of approved therapies.  200:133-139. 2019

Patient registries in idiopathic pulmonary fibrosis.  200:160-167. 2019

Reply to Finotti et al..  199:1444-1445. 2019

Resequencing study confirms that host defense and cell senescence gene variants contribute to the risk of idiopathic pulmonary fibrosis.  200:199-208. 2019

Transcriptomic signatures in sepsis and a differential response to steroids from the VaNISH randomized trial.  199:980-986. 2019

ADAM9: A damaging player in chronic obstructive pulmonary disease.  198:1465-1466. 2018

Nosocomial pneumonia elicits an endothelial proteinopathy: Evidence for a source of neurotoxic amyloids in critically ill patients.  198:1575-1578. 2018

Longitudinal phenotypes and mortality in preserved ratio impaired spirometry in the COPDGene study.  198:1397-1405. 2018

Macrophage Rac2 is required to reduce the severity of cigarette smoke-induced pneumonia.  198:1288-1301. 2018

A multicenter randomized controlled trial of Zephyr Endobronchial Valve treatment in heterogeneous emphysema (LIBERATE).  198:1151-1164. 2018

Ataluren, a new therapeutic for alpha-1 antitrypsin-deficient individuals with nonsense mutations.  198:1099-1102. 2018

Protein tyrosine phosphatase-N13 promotes myofibroblast resistance to apoptosis in idiopathic pulmonary fibrosis.  198:914-927. 2018

Maternal smoking induces acquired CFTR dysfunction in neonatal rats.  198:672-674. 2018

Reversing mechanoinductive DSP expression by CRISPR/dCas9–mediated epigenome editing.  198:599-609. 2018

Changes in lung clearance index in preschool-aged patients with cystic fibrosis treated with ivacaftor (GOAL): A clinical trial.  198:526-528. 2018

Defining impaired respiratory health a paradigm shift for pulmonary medicine.  198:440-446. 2018

Early chronic obstructive pulmonary disease or early detection of mild disease?.  198:411-412. 2018

Future research directions in pneumonia.  198:256-263. 2018

Things we “kNOw” and do not “kNOw” about pulmonary hypertension.  198:151-152. 2018

Exacerbations of chronic obstructive pulmonary disease and cardiac events a post hoc cohort analysis from the SUMMIT randomized clinical trial.  198:51-57. 2018

Control of breathing in preterm infants: Neonatal ICU and beyond.  197:1518-1520. 2018

Generic respiratory symptoms and branded lung diseases: Same Difference?.  197:1521-1523. 2018

HIV gp120 in the lungs of antiretroviral therapy-treated individuals impairs alveolar macrophage responses to pneumococci.  197:1604-1615. 2018

Respiratory symptoms in young adults and future lung disease the cardia lung study.  197:1616-1624. 2018

Ivacaftor-treated patients with cystic fibrosis derive long-term benefit despite no short-term clinical improvement.  197:1483-1486. 2018

Reply to shah et al..  197:1363-1364. 2018

Does extracorporeal membrane oxygenation improve survival in pediatric acute respiratory failure?.  197:1177-1186. 2018

Novel method for noninvasive sampling of the distal airspace in acute respiratory distress syndrome.  197:1027-1035. 2018

MicroRNA-145 antagonism reverses TGF-b inhibition of F508del CFTR correction in airway Epithelia.  197:632-643. 2018

Randomized controlled trial of urokinase versus placebo for nondraining malignant pleural effusion.  197:502-508. 2018

Quantitative evidence for revising the definition of primary graft dysfunction after lung transplant.  197:235-243. 2018

Cardiac morphometry on computed tomography and exacerbation reduction with β-blocker therapy in chronic obstructive pulmonary disease.  196:1484-1488. 2017

Signs of gas trapping in normal lung density regions in smokers.  196:1404-1410. 2017

Home monitoring of patients with cystic fibrosis to identify and treat acute pulmonary exacerbations eICE study results.  196:1144-1151. 2017

Recovery from critical illness: Physical rehabilitation in the intensive care unit, timing of persistent critical illness, and caregiver outcomes.  196:1068-1070. 2017

Vascular endothelial mitochondrial function predicts death or pulmonary outcomes in preterm infants.  196:1040-1049. 2017

Computed tomography measure of lung at risk and lung function decline in chronic obstructive pulmonary disease.  196:569-576. 2017

Severe pneumococcal pneumonia causes acute cardiac toxicity and subsequent cardiac remodeling.  196:609-620. 2017

FEV1 decline in patients with chronic obstructive pulmonary disease: Reply.  195:1677. 2017

Pulmonary hypertension and precision medicine through the "omics" looking glass.  195:1558-1560. 2017

Reply: FEV1 Decline in Patients with Chronic Obstructive Pulmonary Disease..  195:1677. 2017

Association between cardiorespiratory fitness and lung health from young adulthood to middle ages.  195:1236-1243. 2017

Effect of fluticasone furoate and vilanterol on exacerbations of chronic obstructive pulmonary disease in patients with moderate airflow obstruction.  195:881-888. 2017

Sequelae of donor-derived mollicutes transmission in lung recipients.  195:687-689. 2017

Acute exacerbations and lung function loss in smokers with and without chronic obstructive pulmonary disease.  195:324-330. 2017

Noninvasive Ventilation of Patients with Acute Respiratory Distress Syndrome: Insights from the LUNG SAFE Study.  195:67-77. 2017

What is in a pattern? that which we call idiopathic pulmonary fibrosis by any other pattern would behave alike!.  195:10-12. 2017

All about Asthma: Association with Obstructive Sleep Apnea, Management, and Overlap with Chronic Obstructive Pulmonary Disease.  194:1423-1425. 2016

National institute of environmental health sciences: 50 years of advancing science and improving lung health.  194:1190-1195. 2016

Discovery of clinically approved agents that promote suppression of cystic fibrosis transmembrane conductance regulator nonsense mutations.  194:1092-1103. 2016

Hidden in plain sight: Lung impairment in ischemic heart disease.  194:528-530. 2016

Reply.  194:522. 2016

Reply: It Is Too Early to Say No Place for High-Frequency Oscillatory Ventilation in Children with Respiratory Failure..  194:522. 2016

Association between functional small airway disease and FEV1 decline in chronic obstructive pulmonary disease.  194:178-184. 2016

Compartmentalization is key in limiting nitric oxide scavenging by cell-free hemoglobin.  193:1072-1074. 2016

Reply.  193:1068-1069. 2016

Reply: Do We Really Know How to Use High-Frequency Oscillatory Ventilation in Critically Ill Children?.  193:1068-1069. 2016

Oxidative modifications of protein tyrosyl residues are increased in plasma of human subjects with interstitial lung disease.  193:861-866. 2016

Early high-frequency oscillatory ventilation in pediatric acute respiratory failure: A propensity score analysis.  193:495-503. 2016

Glycolytic reprogramming in myofibroblast differentiation and lung fibrosis.  192:1462-1474. 2015

Recovery of acquired cystic fibrosis transmembrane conductance regulator dysfunction after smoking cessation.  192:1521-1524. 2015

Endothelin-1 pathway polymorphisms and outcomes in pulmonary arterial hypertension.  192:1345-1354. 2015

A fragment in time: Elastin peptides and progression of emphysema.  192:1141-1143. 2015

Loss of Lung Health from Young Adulthood and Cardiac Phenotypes in Middle Age..  192:76-85. 2015

Neutrophil extracellular traps are pathogenic in primary graft dysfunction after lung transplantation.  191:455-463. 2015

A randomized, placebo-controlled trial of roflumilast effect on proline-glycine-proline and neutrophilic inflammation in chronic obstructive pulmonary disease.  192:934-942. 2015

Blue Journal Conference: Aging and susceptibility to lung disease.  191:261-269. 2015

Cardiotoxicity during invasive pneumococcal disease.  191:739-745. 2015

Noninvasive computed tomography-based risk stratification of lung adenocarcinomas in the national lung screening trial.  192:737-744. 2015

Extracorporeal membrane oxygenation for acute respiratory failure in adults: The need for pulmonary INTERMACS.  190:1321-1322. 2014

Is pulmonary hypertension a metabolic disease?.  190:973-975. 2014

An aberrant leukotriene A4 hydrolase-proline-glycine-proline pathway in the pathogenesis of chronic obstructive pulmonary disease.  190:51-61. 2014

Plasma complement levels are associated with primary graft dysfunction and mortality after lung transplantation.  189:1564-1567. 2014

Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy.  189:1503-1508. 2014

C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis.  189:966-974. 2014

Reply.  189:869-870. 2014

Tertiary lymphoid structures target the antitumor immune response to lung cancer.  189:767-769. 2014

Genetic variation in the prostaglandin E2 pathway is associated with primary graft dysfunction.  189:567-575. 2014

A functional anatomic defect of the cystic fibrosis airway.  190:421-432. 2014

A novel tumor necrosis factor-mediated mechanism of direct epithelial sodium channel activation.  190:522-532. 2014

Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.  190:175-184. 2014

Genome-wide association identifies regulatory loci associated with distinct local histogram emphysema patterns.  190:399-409. 2014

Integrative "omic" analysis of experimental bacteremia identifies a metabolic signature that distinguishes human sepsis from systemic inflammatory response syndromes.  190:445-455. 2014

Thromboendarterectomy for chronic thromboembolic pulmonary hypertension in hereditary hemorrhagic telangiectasia.  189:112-114. 2014

Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and exhaled nitric oxide.  188:1407-1412. 2013

Sleep apnea is associated with subclinical myocardial injury in the community: The ARIC-SHHS study.  188:1460-1465. 2013

Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator function.  188:1321-1330. 2013

AECOPD: Acute exacerbations of chronic obstructive cardiopulmonary disease?.  188:1046-1048. 2013

S100A8/A9 proteins mediate neutrophilic inflammation and lung pathology during tuberculosis.  188:1137-1146. 2013

High-frequency oscillatory ventilation, microRNAs in pulmonary hypertension, and gastric residual volumes..  188:508-509. 2013

Computed tomographic measures of pulmonary vascular morphology in smokers and their clinical implications.  188:231-239. 2013

Cyclooxygenase-2 inhibits T helper cell type 9 differentiation during allergic lung inflammation via down-regulation of IL-17RB.  187:812-822. 2013

Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses.  187:768-775. 2013

Clinical risk factors for primary graft dysfunction after lung transplantation.  187:527-534. 2013

A young hispanic with c.1646G>A mutation exhibits severe cystic fibrosis lung disease: Is ivacaftor an option for therapy?.  186:694-696. 2012

Genome-wide association studies identify CHRNA5/3 and HTR4 in the development of airflow obstruction.  186:622-632. 2012

Altered DNA methylation profile in idiopathic pulmonary fibrosis.  186:525-535. 2012

Variation in PTX3 is associated with primary graft dysfunction after lung transplantation.  186:546-552. 2012

Retinoic acid-related orphan receptor-α is induced in the setting of DNA damage and promotes pulmonary emphysema.  186:412-419. 2012

Modern age pathology of pulmonary arterial hypertension.  186:261-272. 2012

A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.  186:88-95. 2012

Update in diffuse parenchymal lung disease 2011.  186:24-29. 2012

Computed axial tomography scans, calories, and computers.  185:584-585. 2012

Lung endothelial Ca ²⁺ and permeability response to platelet-activating factor is mediated by acid sphingomyelinase and transient receptor potential classical 6.  185:160-170. 2012

Obesity and primary graft dysfunction after lung transplantation: The lung transplant outcomes group obesity study.  184:1055-1061. 2011

A Trojan horse strategy to deliver amikacin to mycobacterial granulomas [1].  184:860. 2011

The missing link between smoking and COPD autoreactivity?.  184:747-749. 2011

Cyclooxygenase-2 regulates Th17 cell differentiation during allergic lung inflammation.  184:37-49. 2011

Active and passive cigarette smoking and acute lung injury after severe blunt trauma.  183:1660-1665. 2011

Prediction of bronchopulmonary dysplasia by postnatal age in extremely premature infants.  183:1715-1722. 2011

ANGPT2 genetic variant is associated with trauma-associated acute lung injury and altered plasma angiopoietin-2 isoform ratio.  183:1344-1353. 2011

Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort.  183:885-890. 2011

Recommended Reading from the University of Alabama Fellows: J. Allen Cooper, Program Director..  183:411-412. 2011

Targeted delivery of amikacin into granuloma.  182:1546-1553. 2010

Urokinase-type plasminogen activator inhibits efferocytosis of neutrophils.  182:1516-1523. 2010

Macrophage migration inhibitory factor promotes tumor growth in the context of lung injury and repair.  182:1030-1037. 2010

Cystic fibrosis pulmonary guidelines: Pulmonary complications: Hemoptysis and pneumothorax.  182:298-306. 2010

Is there a doctor in the house? The downside of 24/7 attending coverage in academic intensive care units.  181:1280-1281. 2010

Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.  181:604-610. 2010

Latent herpesvirus infection augments experimental pulmonary fibrosis.  181:465-477. 2010

Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary disease.  181:438-445. 2010

What is autoimmunity and why is it likely to be important in chronic lung disease?.  181:4-5. 2010

Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction.  180:1010-1015. 2009

Deletion of Pten expands lung epithelial progenitor pools and confers resistance to airway injury.  180:701-712. 2009

Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease.  180:499-505. 2009

Impact of the lung allocation score on lung transplantation for pulmonary arterial hypertension.  180:468-474. 2009

Are telomere lengths of leukocytes from patients with pulmonary fibrosis really genetically determined?.  179:852. 2009

Bcl-2 suppresses sarcoplasmic/endoplasmic reticulum Ca21-ATPase expression in cystic fibrosis airways role in oxidant-mediated cell death.  179:816-826. 2009

Biologic lung volume reduction in advanced upper lobe emphysema phase 2 results.  179:791-798. 2009

Antiinflammatory effects of hydrogen peroxide in neutrophil activation and acute lung injury.  179:694-704. 2009

Gamma Delta T Cells Attenuate Pulmonary Fibrosis through the Production of IP-10.  179. 2009

Regulation of Thy-1 Expression by Histone Modifications in Lung Fibroblast..  179. 2009

STAT4-Dependent, T-Bet Independent Lung Immune Responses to Pneumocystis.  179. 2009

The Absence of Hck, Fgr and Lyn Tyrosine Kinases Augments Lung Innate Immune Responses to Pneumocystis.  179. 2009

Potential role of high-mobility group box 1 in cystic fibrosis airway disease.  178:822-831. 2008

CD28 down-regulation on CD4 T cells is a marker for graft dysfunction in lung transplant recipients.  178:765-773. 2008

Mitochondrial respiratory complex I regulates neutrophil activation and severity of lung injury.  178:168-179. 2008

Screening contacts of tuberculosis: Overcoming obstacles with an old tool.  177:939-940. 2008

Autoantibodies in patients with chronic obstructive pulmonary disease.  177:156-163. 2008

BUILD-1: A randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.  177:75-81. 2008

On treatment outcomes of patients with HIV and tuberculosis [1].  177:121. 2008

Ozone, a malady for all ages.  176:107-108. 2007

Importance of phosphoinositide 3-kinase γ in the host defense against pneumococcal infection.  175:958-966. 2007

One more prediction rule: Has anything new been added? [1].  175:743. 2007

Association of protein C and type 1 plasminogen activator inhibitor with primary graft dysfunction.  175:69-74. 2007

Children's secondhand smoke exposure in African-American families 2007

Measurement of secondhand smoke exposure in children using a point of care urine dipstick assay for cotinine 2007

Modulatory role for retinoid-related orphan receptor α in allergen-induced lung inflammation.  174:1299-1309. 2006

Long-term oxygen treatment in chronic obstructive pulmonary disease: recommendations for future research: An NHLBI workshop report.  174:373-378. 2006

Leflunomide prevents alveolar fluid clearance inhibition by respiratory syncytial virus.  173:673-682. 2006

Reactive species mediate inhibition of alveolar type II sodium transport during mycoplasma infection.  173:334-344. 2006

Bombesin-like peptides: Modulators of inflammation in acute lung injury?.  173:1-2. 2006

Reevaluating neonatal resuscitation with 100% oxygen.  172:1360-1361. 2005

The mysterious pulmonary brush cell: A cell in search of a function.  172:136-139. 2005

Oleic acid damages ion transport promotes alveolar edema: The dark side of healthy living.  171:424-425. 2005

Loss of bone density with inhaled triamcinoline in lung health study II.  170:1302-1309. 2004

Immunostimulatory oligonucleotides attenuate airways remodeling in allergic monkeys.  170:1153-1157. 2004

Asthma self-management, self-efficacy, and resilience in adolescents attending asthma camp 2004

Parent and child agreement on questionnaires for asthma case detection 2004

A Genome-Wide Scan of Pulmonary Function Measures in the National Heart, Lung, and Blood Institute Family Heart Study.  167:1528-1533. 2003

Statin use is associated with improved function and survival of lung allografts.  167:1271-1278. 2003

Nontuberculous mycobacteria: I: Multicenter prevalence study in cystic fibrosis.  167:828-834. 2003

Secondhand smoke exposure and school-age children 2003

A decision tree for tuberculosis contact investigation.  166:1122-1127. 2002

Fibrinolysis in the pleural space. Breaking the bonds that bind.  166:909-910. 2002

ATS statement: Guidelines for the six-minute walk test.  166:111-117. 2002

Oligoclonal CD4⁺ T cell expansions in lung transplant recipients with obliterative bronchiolitis.  165:1439-1444. 2002

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial.  165:800-804. 2002

Genetic loci influencing lung function: A genomewide scan in the Framingham Study.  165:795-799. 2002

Asthma education in elementary school children and teachers 2002

ETS avoidance behaviors 2002

Heritability of longitudinal change in lung function: The Framingham study.  164:1655-1659. 2001

Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis.  164:193-196. 2001

Attenuation of interleukin 8-induced nasal inflammation by an inhibitor peptide.  163:1198-1205. 2001

Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis.  163:1683-1692. 2001

Increased levels of nitrate and surfactant protein A nitration in the pulmonary edema fluid of patients with acute lung injury.  163:166-172. 2001

Nitric oxide and nitrotyrosine in the lungs of patients with acute respiratory distress syndrome.  163:503-510. 2001

Trends in asthma prevalence and morbidity in Head Start graduates 2001

Use of a long-acting inhaled β2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease.  163:1087-1092. 2001

Talc induces apoptosis in human malignant mesothelioma cells in vitro..  161:595-600. 2000

Asthma prevalence and morbidity in Head Start Graduates 2000

Cyclophosphamide prevents systemic keratinocyte growth factor-induced up-regulation of surfactant protein A after allogeneic transplant in mice.  162:1884-1890. 2000

DETANONOate, a nitric oxide donor, decreases amiloride-sensitive alveolar fluid clearance in rabbits.  161:1154-1160. 2000

Heterogeneous geographic distribution of inner city pediatric asthma admissions in Birmingham 2000

Management of malignant pleural effusions.  162:1987-2001. 2000

Protein nitration, metabolites of reactive nitrogen species, and inflammation in lung allografts.  161:2035-2042. 2000

Results of a school-based multi-stage screening procedure for asthma 2000

School environments and children with asthma 2000

Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease: The lung health study.  161:381-390. 2000

Talc induces apoptosis in human malignant mesothelioma cells in vitro.  161:595-600. 2000

Helper T cell type 1 and 2 cytokines regulate C-C chemokine expression in mouse pleural mesothelial cells..  159:1653-1659. 1999

Acid-induced lung injury: Protective effect of anti-interleukin-8 pretreatment on alveolar epithelial barrier function in rabbits.  160:1450-1456. 1999

Helper T cell type 1 and 2 cytokines regulate C-C chemokine expression in mouse pleural mesothelial cells.  159:1653-1659. 1999

Identification of questions that best predict new diagnosis of asthma in children 1999

Interleukin-8 mediates injury from smoke inhalation to both the lung endothelial and the alveolar epithelial barriers in rabbits.  160:1443-1449. 1999

Leptin prevents respiratory depression in obesity.  159:1477-1484. 1999

Reporting of symptoms in childhood asthma: Parent and child comparisons 1999

Advances in prevention and education in lung disease.  157. 1998

Segregation analysis of pulmonary function among families in the framingham study.  157:1445-1451. 1998

Talc-induced expression of C-C and C-X-C chemokines and intercellular adhesion molecule-1 in mesothelial cells.  158:971-978. 1998

Upregulation of xanthine oxidase by lipopolysaccharide, interleukin-1, and hypoxia: Role in acute lung injury.  158:299-305. 1998

Biological markers of acute lung injury: Prognostic and pathogenetic significance.  155:1187-1205. 1997

The epithelium as a target of glucocorticoid action in the treatment of asthma..  154:S16-S19. 1996

Acute safety and effects on mucociliary clearance of aerosolized uridine 5'-triphosphate ± amiloride in normal human adults.  154:217-223. 1996

Aerosolized cyclosporine in lung recipients with refractory chronic rejection.  153:1451-1455. 1996

Lung injury after hepatoenteric ischemia-reperfusion: Role of xanthine oxidase.  154:1364-1369. 1996

The epithelium as a target of glucocorticoid action in the treatment of asthma.  154. 1996

Transmission of Mycobacterium tuberculosis to recipients of single lung transplants from the same donor.  153:1166-1168. 1996

Clinical risk factors for pulmonary barotrauma: A multivariate analysis.  152:1235-1240. 1995

Delivery and distribution of aerosolized cyclosporine in lung allograft recipients.  151:516-521. 1995

Hyperoxic lung injury reduces exogenous surfactant clearance in vivo.  151:1843-1847. 1995

Laboratory contamination of Mycobacterium tuberculosis cultures.  152:1702-1704. 1995

Resistance of the alveolar epithelium to injury from septic shock in sheep.  151:1093-1100. 1995

Development of pulmonary infection in mice inoculated with Blastomyces dermatitidis conidia..  149:500-509. 1994

Measures for use in asthma clinical research. Overview of the NIH workshop..  149:S1-S8. 1994

A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation.  150:146-152. 1994

Development of pulmonary infection in mice inoculated with Blastomyces dermatitidis conidia.  149:500-509. 1994

Load detection in subjects with sleep-induced upper airway obstruction.  149:727-730. 1994